Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Tenapanor is a novel phosphate-lowering agent that inhibits the intestinal sodium-hydrogen exchanger 3 (NHE3). Its theoretical mechanism of action suggests that it influences by reducing intestinal sodium absorption. However, there is limited clinical evidence on the hemodynamic effects of tenapanor. We evaluated the effects of tenapanor on fluid dynamics and blood pressure in patients undergoing peritoneal dialysis (PD).
This single-arm, prospective observational study enrolled 10 patients with PD and hyperphosphatemia who were newly initiated on tenapanor. Body composition was measured using bioelectrical impedance analysis (BIA) with a multifrequency BIA analyzer (MC-780MA-N, TANITA, Tokyo, Japan) at baseline and at 1 and 3 months after the initiation of tenapanor treatment to assess changes in various parameters.
At 1-month follow-up, significant transient reductions were observed in total body water content (median decrease from 41.1 to 37.5 L, p = 0.02), intracellular water (p = 0.02), and extracellular water (p = 0.02). However, all parameters returned to baseline levels at 3-month follow-up. In contrast, systolic blood pressure significantly decreased from 139.2 ± 14.2 mmHg at baseline to 127.8 ± 9.8 mmHg at 3 months (p = 0.03), and diastolic blood pressure decreased from 83.5 ± 12.0 to 76.8 ± 10.0 mmHg (p = 0.04).
After 1 month of treatment with tenapanor, patients with PD experienced a reduction in fluid volume. However, by the third month, the fluid volume returned to its original levels, with a noticeable decrease in blood pressure. The antihypertensive effect of tenapanor suggests the involvement of mechanisms other than transient reduction in fluid volume. However, since this was a small-sample study, larger and long-term studies are required to validate this hypothesis.
